PDL-1 expression is being extensively used in a variety of neoplasms to inform therapeutic decisions regarding the use of PD/PD-L1 inhibition, the most prevalent example being non-small-cell lung carcinoma (NSCLC). Here, CD274 is linked to non-small cell lung carcinoma.